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Non-syndromicInfertility, deﬁned as the inability to conceive after 1 year of unprotected intercourse, is a healthcare problem
that has a worldwide impact. Male factors are involved in at least half of these cases of infertility. Despite
33 years of assisted reproductive activities, a considerable number of cases (25–30%) remain idiopathic.
This situation can be explained by a poor understanding of the basic mechanisms driving male and female
gametogenesis. Compared to multi-organ pathologies, only a few non-syndromic genetic causes of human
infertility have been described so far, despite the fact that it is estimated that some infertility cases could
be explained by genetic causes and that over 200 infertile or subfertile genetic mouse models have been
described. So far, very little has been discovered in the ﬁeld of human male reproductive genetics. Conse-
quently, genetic tests proposed to infertile couples are limited, although worldwide efforts devoted to the
ﬁeld of human genetics of infertility are expected to provide new genetic tests in the near future. We present
the requirements for performing informative genetics studies in the ﬁeld of infertility, the techniques used
and the results obtained so far. This article is part of a Special Issue entitled: Molecular Genetics of Human
Reproductive Failure.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Infertility, deﬁned as the inability to conceive after 1 year of
unprotected intercourse [1], is a healthcare problem that has a world-
wide impact. Based on a recent report, the prevalence of infertility
was estimated to be 9%. This represents more than 70 million infertile
women, of whom more than 40 million are seeking infertility treat-
ment [2]. Male factors are involved in at least half of these cases of
infertility [3]. Infertility in men can be due to many causes. Among
these cases, some of them are clearly part of genetic syndromes. In-
deed, infertility is associated with other complex phenotypes such
as sex reversal syndrome (involving genes such as SOX9, SRY, and
NROB1), hypogonadotropic–hypogonadism defects (involving genes
such as GNRH, KAL, PC1, GNRHR, LEP, and PCSK1), myotonic dystrophy
(gene DMPK), a mild form of cystic ﬁbrosis and many others [4]. For
example, mutations in the cystic ﬁbrosis transmembrane conductancelar Genetics of Human Repro-
t de Biologie Moléculaire et
echerche Médicale (INSERM)
RS) UMR 1704/Université de
rights reserved.regulator (CFTR) gene are detected in infertile men exhibiting azoo-
spermia with congenital bilateral absence of vas deferens (CBAVD)
[5]. Men with CBAVD undergo normal or slightly reduced spermato-
genesis and present clinical cystic ﬁbrosis symptoms, suggesting that
CBAVD is a mild form of this syndrome [5]. Compared to these multi-
organ pathologies, only few non-syndromic genetic causes of human
infertility have been described so far.
Despite 33 years of assisted reproductive activities, a considerable
number of cases (25–30%) remain idiopathic [1,6]. This situation
can be explained by a poor understanding of the basic mechanisms
driving male and female gametogenesis, despite the fact that some in-
fertility cases could be explained by genetic causes [1,7] and that over
200 infertile or subfertile genetic mouse models have been described
[4]. This number gives an idea of the number of genes that could be
involved in male and female gametogenesis and, consequently, the
complexity of the process. So far, very little has been discovered in
the ﬁeld of human male reproductive genetics. This slow progress
has two main causes. (i) Clinical evaluations are preliminary and
often limited to the presence or absence of spermatozoa in the ejacu-
late. This has been reinforced by the advent of the intracytoplasmic
sperm injection (ICSI) technique, which requires a very limited num-
ber of spermatozoa, even immotile ones, to fertilize the cohort of
oocytes. (ii) Spermatogenesis is a highly sophisticated process involv-
ing complex molecular pathways requiring hundreds of genes. Con-
sequently, genetic tests proposed to infertile couples are limited to
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deletion screening [1]. The worldwide efforts devoted to the ﬁeld
of human genetics of infertility are expected to provide new genetic
tests in the near future. At the present time the ﬁeld is mainly, but
not exclusively, concentrating its effort on male genetics of infertil-
ity. Indeed, because of the easy access to male gametes, diagnoses
are of better quality, allowing a better categorization of the dif-
ferent phenotypes, which is fundamental for carrying out genetic
studies.
In this review, we will focus on non-syndromic genetic defects
affecting human male gametogenesis, presenting a monogenic auto-
somal recessive mode of transmission. We present the requirements
for performing informative genetics studies in the ﬁeld of infertility,
the techniques used and the results obtained so far.Gene screening within
the region(s)
Fig. 1. Linkage analysis. (A) Positional cloning procedure. The positional cloning proce-
dure used to identify candidate genes. A ﬁrst critical step is the recruitment of the
patients. Two groups of patients are of interest: (1) patients presenting a familial infer-
tility, where the families contain at least two infertile members, and (2) patients from
a small isolated geographic area or tribes, where the abnormality has a relatively high
occurrence. In both cases, patients should present a non‐syndromic infertility. A whole
genome scan by SNP microarray is performed in order to select a locus shared only by
the patients and absent in non‐affected ones. Once the region is deﬁned, a bioinfor-
matics screen is performed to select candidate genes within the region. (B) Principle
of homozygosity mapping. A patient with a rare genetic disorder resulting from consan-
guineous parents inherited a mutation (M) on both chromosomes, which was present
at the heterozygous state in a common ancestor (great-grandmother in this diagram).
The polymorphic markers located in the chromosomal region around the gene are rep-
resented by different colors and letters depending on the alleles. Because of various
events of meiotic recombination (represented by crosses), the alleles of markers far
from the gene change and are therefore heterozygous in the patient, while markers
close to the mutated gene are transmitted in a block (called haplotype) from the
great-grandmother and are therefore in the homozygous state in the patient. They
deﬁne a region of homozygosity by descent (framed region).2. Requirements for the identiﬁcation of mutated genes in
human infertility
The ﬁrst major requirement for identifying mutated genes in
infertile patients is the quality of the clinical diagnosis. Indeed, any
improper diagnosis will bias the selection of patients to be included
in the study and introduce confusion in the analysis, rendering the
genetic analysis difﬁcult or even impossible.
Different causes have been described for male infertility. Defective
sperm can be due to the male partner not producing any spermatozoa
at all (azoospermia) or in insufﬁcient numbers (oligozoospermia),
without adequate motility (asthenozoospermia), without normal
morphology (teratozoospermia) or a combination of these defects.
Thus, the clinical features of male infertility vary from azoospermia
to oligoasthenoteratozoospermia.
In order to eliminate frequent causes of oligozoospermia or azoosper-
mia, a pre-screen of the recruited patients has to be performed. Indeed,
chromosomal abnormalities including both numerical (aneuploidy)
and structural aberrations (translocations/inversions) account for 5% of
oligozoospermia and 15% of non-obstructive azoospermia (NOA) [8].
For instance, Klinfelter syndrome (XXY), the most common abnormality
found in NOA [9], causes a maturation arrest of spermatogenesis at
the primary spermatocyte stage. Furthermore, microdeletions of the
Azoopermia factor region (AZF) of the Y chromosome are frequently ob-
served in oligozoospermic to azoospermic men [10]. It should be noted
that external factors, such as environmental pollutants on human game-
togenesis, may also have potential deleterious effects.
The second major requirement is the ability to study informative
patients. Indeed, nonetheless geneticists need well diagnosed patients,
but they need whenever possible large families or cohorts of patients.
Two approaches are commonly used to identify genetic causes of
pathologies, and these can also be applied to the genetics of infertility:
reverse and forward genetics [7]. The reverse approach, also known as
the candidate gene approach, is initiated by selecting genes from infer-
tile animals, mainly mouse models, assuming that the gene function is
conserved through evolution. Such an approach needs manywell char-
acterized patients and a large amount of time. So far, the discoveries
resulting from this approach have been limited [11–17]. This is probably
due to the great genetic heterogeneity and the limited number of
patients tested.
Forward genetics, also known as positional cloning or descent
studies, beneﬁt from the recent and ongoing evolutions in molecular
biology. Indeed, new powerful tools are continuously being devel-
oped and have reached the scale of whole genome analysis, facilitat-
ing the identiﬁcation of recessive autosomal mutations. The main
approach, homozygosity mapping, is based on genotyping studies
and aims to investigate, for a single patient, thousands of single nucle-
otide polymorphisms (SNPs) simultaneously on a microarray. The
success of homozygosity mapping studies strictly depends on the
availability of patients and their rigorous selection (Fig. 1).3. Technologies
Asmentioned above, the reverse or candidate genes approach is ini-
tiated by selecting candidates genes based, mainly, on mouse models.
As soon as a convergence of phenotypes is observed between a speciﬁc
mutatedmouse gene and a human phenotype, mutations in the human
ortholog gene can be screened for [7].
Forward genetics or positioning cloning is based on the whole
genome scan by SNP microarray technology, which allows the identi-
ﬁcation of homozygous regions shared by affected siblings of the
same family and absent in non‐affected siblings [18,19]. The candidate
regions, selected on the basis of consecutive homozygous SNPs, are
then screened using a genome browser in order to list the candidate
genes (Fig. 1). The genes are ranked according to their expression pro-
ﬁle, which in this casemust be predominant in the testes, and their po-
tential function. Once genes are chosen, PCR and sequencing of all
exons and exon/intron junctions are performed in order to highlight
the mutation involved in the patient infertility.
SNP microarrays have tremendous advantages over previous
genotyping methods as they are very dense and cover the whole ge-
nome [18,19]. It is a fast technique that requires only a small amount
of genomic DNA (250 ng). In contrast, genomic regions generated
by homozygosity mapping are generally multiple megabases in size
and can contain multiple genes. Therefore, the identiﬁcation of the
mutated gene from a large number of candidates is expensive and
time consuming. This is where the number of patients or the size of
the family is of great importance. Indeed, the higher the number of
siblings in the family or the larger the patient cohort, the smaller
the homozygous region should be, limiting the number of candidate
genes to be screened.
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more affected patients, as well as two or more unaffected patients
from families with some degree of consanguinity, or (ii) a larger
group of patients from a restricted area or living in a limited socio-
cultural enclave where the abnormality seems to have a quite high
occurrence, which should correspond to a founder effect. Patients
studied in the case of autosomal recessive infertility must present a
non-syndromic infertility with a homogeneous abnormality of the
spermatogenesis. The non-syndromic character implies that patients
are healthy and do not present any other pathology.
Sequencing highlights variations that can have different origins.
They can correspond to polymorphisms, having no functional conse-
quences, or mutations affecting the function of the resulting protein.
According to the type of variation, they can be easily categorized as
mutations. This is the case when part of the gene is deleted or when
the alteration introduces a premature stop codon, but most of time
the interpretation is more complex and rigorous controls are needed.
For this, different possibilities are now available. One classical method
is to check whether the variation/mutation is found in at least 200
sequenced healthy controls matching the same geographic region
and/or same ethnicity of patients. For this purpose, controls must
have proven fertility or normal spermatogenesis or, in other words,
they should have conceived without any medical assistance. It is
now also possible to check databases that collect human sequences
and repertory polymorphisms among the human population (dbSNP
[20] and 1000 genomes project [21]). More recently, software systems
have been developed that are able to predict, with some limitations,
whether alterations will or will not have functional consequences on
the produced protein (SIFT and PolyPhen v2 [22,23]). Whatever the
method used, the best way to prove the effect of a mutation on a pro-
tein is to set up a biological functional test. In the case of genetics of
infertility, this is very challenging because genes involved in male in-
fertility are often mainly, if not exclusively, expressed by the testes
from which biopsies are not easily collected. There is also a dramatic
lack of cellular models, for example carrying on a meiosis, that can
be explored in vitro.
As soon as the high throughput sequencing technology becomes
affordable, it is likely to largely replace the other previous techniques,
which are for the moment must cheaper but less powerful.
Recently, a new method has promised to speed up discovery of
the genetic causes of disease by allowing the parallel sequencing of
millions of sequences at high throughput: next generation sequenc-
ing (NGS). NGS combined with enrichment technologies is used to
sequence the exome (the set of all coding exons representing 1% of
the human genome) in order to discover most of the disease-related
variations in exons [24]. In other words, this technique allows the
identiﬁcation of protein coding mutations, including missense, non-
sense, splice site, and small deletion or insertion mutations. Exome
sequencing has become a powerful and efﬁcient strategy for identify-
ing the genes responsible for Mendelian disorders and complex
diseases [25–29] and may be applicable in the case of infertility. The
challenge in this technique lies in highlighting the particular muta-
tion responsible for the disease, since the genome of a single individ-
ual will reveal about 25 000 variants [29]. A critical step involves
ﬁltering of known polymorphisms present in the general population,
using data from dbSNP [20], the HapMap project [30], etc. These poly-
morphisms are unlikely to cause disease. Further ﬁltering steps can
also be applied to remove: (i) synonymous mutations that do not
alter the amino acid sequence, (ii) variants that are predicted in silico
not to affect protein structure or function and iii) variants which
do not ﬁt the mode of disease inheritance and do not segregate
with the disease (in families). Although, exome sequencing has prov-
en its worth in genetics, this technique has some limitations related
to the coverage of the entire exons, which will never reach 100%
[31], the poor capture and sequencing of a causative gene, the
mismapped reads or alignment errors that can generate false variants,the difﬁculty in detecting genomic rearrangements such as large dele-
tions and duplications and ﬁnally the causative gene is not in the
target deﬁnition because is not yet referred in the Refseq database.
Analytical failure mainly concerns the false positive and false negative
calls. False positive calls result in detection of candidate genes that
cannot be logically eliminated by ﬁltering and are often observed in
segmental duplications and pseudogenes. False negative calls result
from the presence of pathogenic variants in the data used as a refer-
ence to eliminate the known variants.
A combination of homozygosity mapping with genome sequenc-
ing may lead to rapid identiﬁcation of the causative mutation for a
disease [32]. The technical locks of whole genome genotyping and
sequencing have now been broken and we believe that the key to suc-
cessfully identifying causative mutations by descent studies depends
on the adequate recruitment of patients. The major limitation of NGS
is the price. Indeed, the technology remains expensive and the analy-
sis requires a multi-disciplinary approach, but the cost is falling very
rapidly and soon it will be the reference technology for investigating
genetic mutations.
4. Outcome of this quest for genes responsible for infertility
Recent identiﬁcation ofmutations inwell-known spermdefects pro-
vides proof of their genetic origins. Indeed, gene mutations have been
identiﬁed for two types of teratozoospermia, namely globozoospermia
and macrocephaly, for asthenozoospermia, for NOA and absence of
oocyte activation.
Globozoospermia is a rare and severe teratozoospermia character-
ized by round headed spermatozoa lacking an acrosome. Two types of
globozoospermia have been described: type I with complete absence
of acrosome and type II with the presence of some sperm with acro-
somes [33]. The acrosome plays a crucial role during fertilization by
allowing spermatozoa to travel through the zona pellucida and to
reach the oocyte cytoplasmic membrane [34]. Therefore, patients
suffering from a complete form of globozoospermia are infertile.
Round headed spermatozoa do not present chromosomal abnormali-
ties [35–37] and pregnancy can be obtained through ICSI, albeit at
a very low frequency [38–43]. Studies based on candidate genes or
on family cases of globozoospermia resulted in the identiﬁcation of
three genes: SPATA16, PICK1 and DPY19L2.
The ﬁrst example of a non‐syndromic male infertility in human
caused by an autosomal gene defect was a mutation in SPATA16
(spermatogenesis associated 16). This gene was identiﬁed by homo-
zygosity mapping while studying a consanguineous Ashkenazi Jew
family where 3 brothers were globozoospermic [44]. SPATA16 is a tes-
tes expressed gene located on 3q26.32. It contains 11 exons encoding
for a 569 amino acid protein, which is highly conserved across mam-
mals. The most conserved domain of the protein is a tetratricopeptide
repeat (TPR) domain, a protein–protein interaction domain commonly,
but not exclusively, found in cochaperone proteins [45]. The affected
brothers show a variation in exon 4 (c.848G>A), altering the last nucle-
otide of the exon and leading to an inappropriate splicing. Themutation
leads to the deletion of exon 4 and disrupts the TPR domain, since 36
amino acids are deleted [44]. PICK1 was identiﬁed by a gene candidate
strategy. Liu et al. screened four candidate genes (GOPC, HRB, CSNK2A2
and PICK1) in 3 globozoospermic type I patients and found a homozy-
gous missense mutation (c.G198A) in exon 13 of the PICK1 gene for
one of these patients [46]. This homozygous mutation altered the
amino acid G393R in the C-terminal part of the protein. PICK1 is a
peripheralmembrane protein involved in protein trafﬁcking and highly
expressed in the brain, testes and pancreas. In the brain, PICK1has a role
in AMPA receptor trafﬁcking and synaptic plasticity [47]. Male Pick1
knockout mice validate these results [48] and surprisingly show an
infertile phenotype. In testes, PICK1 is a Golgi derived proacrosomal
granule protein expressed in round spermatids. Male Pick1 null mice
showed a fragmented acrosome due to the fusion failure of acrosomal
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structures during the cap phase [49]. Since the mutation identiﬁed by
Liu et al. does not change a highly conserved amino acid and no func-
tional consequences have been shown, caution should be taken not to
over interpret this result without additional data.
In an older work using a candidate approach, we unsuccessfully
screened 6 globozoospermic patient for mutations in CSNK2A2 [14].
DPY19L2 was identiﬁed independently by 2 groups [50,51], the
ﬁrst studying family cases [50] and the second, a cohort of patients
[51]. The gene was identiﬁed by homozygosity mapping and found
to be associated with the complete form of globozoospermia, as for
the two genes described above: SPATA16 and PICK1. DPY19L2 is a
member of the DPY19L family, which has undergone multiple dupli-
cations during evolution [52]. DPY19L2 is located on 12q14.2, has 22
coding exons, is ﬂanked by two low copy repeat (LCR) regions sharing
96.5% of identity and encodes for a transmembrane protein. In our
initial study, we found that 19% of the analyzed patients were deleted
for DPY19L2 [50]. The second study found amuch higher rate of deleted
patients (75%) [51]. The difference is most probably due to a broader
distribution in our cohort of patients, since in the second study the
patients were mostly Tunisians. Both teams show that the mechanism
underlying the deletion ismost probably due to a non‐allelic homologous
recombination (NAHR) between the LCR. Indeed, NAHR mechanisms
are mediated by highly homologous repetitive sequences, such as Alu
sequences, and account for some of the non-recurrent rearrangements
[53]. Because we found different breakpoints in patients originating
from different regions, we could exclude an ancient founder effect and
suggested that the deletion may rely on the architectural feature of the
locus [50].
By searching copy-number variant (CNV) databases at theDPY19L2
locus, we could identify 86 CNVs, including 64 duplications and 22
heterozygous deletions for the 4886 patients studied, but no homozy-
gous deletion was reported. We observed about three times more
duplications than deletions, which is surprising because in most NHAR
cases studied, deletions are more frequent than duplications [53]. The
search also allowed us to calculate a precise frequency of heterozygous
deletion in the surrounding region of DPY19L2 of 1/222, implying an
overall disease risk of ~1/200,000 [50].
In order to better estimate the contribution of DPY19L2 in glob-
ozoospermia, we screened a larger cohort including 64 globozoospermic
patients. Twenty of the new patients were homozygous for the DPY19L2
deletion, and 7 were compound heterozygous for both this deletion and
a point mutation. We also identiﬁed 4 additional mutated patients. The
ﬁnal mutation load in our cohort is 66.7% (36/54). Out of 36 mutated
patients, 69.4% are homozygous deleted, 19.4% heterozygous composite
and 11.1% showed a homozygous point mutation. The mechanism
underlying the deletion is a non-allelic homologous recombination
(NAHR) between the ﬂanking LCRs [54].
Little is known concerning the function of this gene. In fact, the
orthologue of DPY19L2 in C. elegans is implicated in the polarization
of neuroblasts, suggesting that this gene may be involved in head
spermatozoa elongation in mice and human.We rejected this hypothe-
sis since we could detect, in the globozoospermic semen, the presence
of well elongated spermatozoa. Instead, we believe that DPY19L2
plays a role in the biogenesis of the acrosome.
For one other teratozoospermia, macrocephalia or enlarged headed
spermatozoa, a gene has been identiﬁed. Indeed, the AURKC gene was
identiﬁed by linkage analysis involving a genome‐wide microsatellite
scan of 10 infertile men with a large headed spermatozoa phenotype
[55]. AURKC is located on 19q13.3-qter, has 7 exons and is highly
expressed in testes. A homozygous deletion in exon 3 (c.144delC) was
detected, which introduces a frameshift leading to a premature stop
codon and resulting in the alteration of the conserved kinase domain
[55]. Aurora kinase C is the last discovered member of an aurora kinase
family, which includes two other members: AURKA and AURKB. All
three are cell cycle regulatory serine/threonine kinases that play anessential role in mitotic cell division [55,56]. Little is known about
AURKC. In mice spermatogenesis, AURKC is involved in chromosome
segregation and cytokinesis, which ﬁts well with the human phenotype
[57]. Indeed, it was shown that all the spermatozoa of these patients are
tetraploid, strongly suggesting the implication of AURKC in the segrega-
tion of chromosomes and/or meiotic cytokinesis, explaining the large
size of the gametes [58].
The founder origin of the (c.144delC) mutation was further con-
ﬁrmed when studying a larger cohort of North African patients. This
study also established a frequency of heterozygotes of over 1 in 50, im-
plying an expected prevalence of 1/10000men. Such a high frequency
is surprising since it makes AURKC infertility among the most frequent
single gene defect in this population. Interestingly, the authors identi-
ﬁed two fertile homozygous females, excluding a fundamental role
of AURKC in female meiosis and conﬁrming the differences between
male and female meiotic mechanisms [58].
Recently, the same group described a second mutation affecting
the splicing of AURKC [59].
Using a combination of both methods (i.e. candidate gene approach
and homozygosity mapping), Avenarius et al. studied two consan-
guineous Iranian families and found insertion mutations in CATSPER1
responsible for sperm immotility in the three asthenozoospermic
patients and segregating as a non-syndromic autosomal recessive
pathology [60]. They initiated their study based on observations made
in the mouse model. Indeed, in mice, the deﬁciency of any one of the
four Catsper genes leads to male infertility by affecting spermatozoa
motility [61,62]. They then performed a homozygositymapping speciﬁc
to the CATSPER locus. In both families, an insertion mutation was
observed. In the ﬁrst one, the mutation (c.539-540insT) introduces a
premature stop codon that could eventually lead to the production of
a truncated protein of 188 amino acids. In the second one, themutation
(c.948-949insATGGC) also introduces a premature stop codon with a
resulting protein of 335 residues. In both cases, even if the protein is
produced, it would lack all six transmembrane domains, abolishing the
CATSPER1 channel activity [60]. Indeed, the CATSPER1 protein is required
for the entry of Ca2+ into the ﬂagellum and for the hyperactivation of the
spermonce they enter the female reproductive tract [63]. Hyperactivation
is necessary for the penetration of the spermatozoa into the oocyte [64].
It could be of interest to investigate whether ICSI could be successfully
offered to treat these patients.
Recently, starting with a candidate gene strategy, Choi et al.
identiﬁed variations in SOHLH1 that could be responsible of non-
obstructive azoospermia (NOA). Indeed, by screening 96 NOA Korean
patients and 159 controls, they identiﬁed 3 variations that could be
responsible for NOA [65]. The functional analysis did not clearly es-
tablish the pathogenicity for two of these variations. Thus, even if
they were not detected in controls, these two variations (c.91T>C
and c.529C>A) should be considered with caution. In vitro analyses
of the third variation showed that it induces a splicing error, resulting
in a truncated protein lacking the last 6 amino acids of the bHLH
domain. This truncated protein was shown to be less potent in acti-
vating the KIT promoter in an in vitro test, [65]. Despite their interest,
these results need conﬁrmation. Indeed, the mutation is found at the
heterozygous status and therefore should have a dominant negative
effect. In addition, the mouse model [66] does not fully phenocopy
what is observed in the only patient for whom a testis anapathology
could be done. A much larger cohort of controls should be tested.
However, the fact that the same mutation has been found in two
independent NOA patients reinforces the hypothesis that the c.346-
1G>A variation can be considered as a mutation.
One more example of a successful candidate gene approach is
the characterization of mutations in PLCζ in a patient for which an
absence of oocyte activation was diagnosed through a mouse func-
tional test. Indeed, the group of De Sutter has elaborated a mouse
oocyte activation test (MOAT) that they apply in case of absence of
fertilization following an ICSI treatment. There are strong arguments
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activation and the calcium oscillations that ensue [67]. In a screen of a
cohort of 9 patients with a negative MOAT, one patient was shown
to be heterozygous composite for two mutations affecting the X and
Y catalytic domains [68,69]. This initial work is very interesting and
deserves a close follow up.
Finally, we would like to mention the striking cases of NR5A1,
which encodes the steroidogenic factor 1 (SF1). NR5A1 mutations
are linked to a wide range of phenotypes, such as male partial
and complete gonadal dysgenesis, associated or not with adrenal
failure, penoscrotal hypospadias, micropenis and primary ovarian
insufﬁciency [70,71]. In a recent report, Bashamboo et al. found
7 healthy patients, suffering only from severe oligozoospermia
or azoospermia, out of 315 screened patients to be mutated for
NR5A1. All the mutations were found in the well conserved hinge
region of the protein [72]. Thus, we have an interesting situation
where, depending on the type of mutations, we can observe a
large variety of phenotypes, with one of them affecting only sper-
matogenesis. We can predict that such a situation, which is somewhat
reminiscent of what is seen for CFTR mutations, will be encountered
with other genes.
We have presented a selected number of examples of recessive
autosomal mutations that impair human male fertility. Dominant
mutations may play an important role, since they could either be
transmitted through the female germline or occur de novo in the
patients. However, no record of this case has been listed so far. In
addition, the failure to identify causative genes in some cases can be
explained by the fact that human gametogenesis is a complex process
and infertility may be the result of multigenic and multifactorial
causes. To overcome this problem, a large cohort of well diagnosed
informative patients must be studied.
These studies are of tremendous importance at different levels.
They represent a unique way to study human gametogenesis and
to decipher the underlying mechanisms, which in turn will have
clinical and fundamental repercussions: (i) patients will beneﬁt by
having a molecular diagnosis followed by appropriate counseling
and care, (ii) the ﬁndings will contribute to a better understanding
of the physiopathological process of human reproduction, (iii) in
the longer term, a better understanding of the genes involved in
spermatogenesis will help to identify the extrinsic factors that com-
promise spermatogenesis and prevent the deterioration of fecun-
dity, (iv) taken together, this should also improve the practice of
artiﬁcial reproductive technologies, not only for mutated patients,
but for all couples.
Couples experiencing male infertility problems should undergo
genetic counseling before pursuing assisted reproductive treatment
in order to suggest an appropriate solution. ICSI cannot be proposed
as a treatment for all cases of infertility. For example, patients with
enlarged head spermatozoa, due to a mutation in AURKC, have
only tetraploid gametes [55] and it is therefore useless to offer
them an ICIS treatment. Moreover, the Y-microdeletion will be
transmitted to the offspring when performing ICSI, resulting in
infertile male children. In contrast, it is reasonable to propose ICSI
treatment for globozoospermic patients, since round headed sper-
matozoa do not present a higher rate of chromosomal abnormalities
[36].
These results will also have broader implications. Indeed, a gen-
eral decline in fertility has been observed, which is obviously not
due to genetic causes but is rather caused, at least in part, by
increased concentrations of environmental endocrine disruptors,
such as environmental oestrogen-like molecules [73,74]. We be-
lieve that a better understanding of spermatogenesis, starting
with in depth knowledge of all the genes involved, will eventually
be instrumental in identifying and understanding the effects of
these toxic chemicals and in ﬁnding solutions to stop their adverse
effects.5. Variations/polymorphisms associated with human
male infertility
Apart from these conclusive results concerning the identiﬁcation
of mutations in single genes responsible for male human infertility, in
the last few years there has been an (too) abundant literature on varia-
tions that are presented as mutations or polymorphisms that could be
associated with a spermatogenesis alteration or could constitute a risk
factor. Most of these studies are based on a candidate gene approach.
These studies have been conducted on a limited number of patients
and controls. In some cases, the ethnicity of the patients and their
controls did not match. Some of the variations have been described as
heterozygous and parents or family members have not been checked
for the presence or absence of the variation. Finally, none of these vari-
ations has been the object of functional studies to validate their delete-
rious effect. Until such studies are performed, these variations should be
considered as polymorphisms. A list of these variations/polymorphisms
can be found in Massart et al. [10].
Two recent studies deserve a more detailed review. The laboratory
of Pr. Carrell performed a genome-wide association study (GWAS) on
52 oligozoospermic, 40 non-obstructive azoospermic (NOA) patients
and 80 controls [75] and expanded their study by analyzing identiﬁed
SNPs on 141 oligospermic and 80 NOA patients and 158 controls [76].
Their results identiﬁed several promising SNPs associated with oligo
or azoospermia, but larger cohorts are needed to deﬁnitively conﬁrm
these associations.
In a much more powerful study, Hu et al. analyzed 2927 NOA
patients and 5734 controls from the Han population and conﬁdently
identiﬁed 3 common variants signiﬁcantly associated with NOA.
One of these variants is close to PRMT6, the second one to PEX10
and the last one to SOX5. All these genes are potentially involved in
spermatogenesis, but no effect of these variants on the level of ex-
pression of the associated genes has been demonstrated so far [77].
Thus, further functional studies are needed, but this work strongly sug-
gests that NOA, like other complex pathologies, is multigenic and that
no single SNP is responsible for a large proportion of azoospermia.
6. Conclusions
Genetics of infertility is a new ﬁeld that will undoubtedly gain im-
portance in the near future, although the term ‘genetics of infertility’
may seem paradoxical. Indeed, genetics involves the study of the
transmission from one generation to the next one of genetic traits,
while infertility studies try to understand why genetic traits cannot
be transmitted to the next generation.
These studies will not only allow the identiﬁcation of genes in-
volved in spermatogenesis, but also risk factors. In particular, it will
allow the establishment of a more comprehensive list of genetic
variation combinations and environmental factors that could lead to
spermatogenesis defects.
Acknowledgements
We are grateful to all team members for the very fruitful and
motivating working environment. We also like to thank Dr. Julie
Thompson for their critical reading of this manuscript. This work was
supported by the French Centre National de la Recherche Scientiﬁque
(CNRS), Institut National de la Santé et de la Recherche Médicale
(INSERM), the Ministère de l'Education Nationale, the Enseignement
Supérieur et de la Recherche, theUniversity of Strasbourg, theUniversity
Hospital of Strasbourg and the Agence de la BioMédecine.
References
[1] C. Krausz, Male infertility: pathogenesis and clinical diagnosis, Best Pract. Res.
Clin. Endocrinol. Metab. 25 (2011) 271–285.
1878 E. El Inati et al. / Biochimica et Biophysica Acta 1822 (2012) 1873–1879[2] J. Boivin, L. Bunting, J.A. Collins, K.G. Nygren, International estimates of infertility
prevalence and treatment-seeking: potential need and demand for infertility
medical care, Hum. Reprod. 22 (2007) 1506–1512.
[3] J. Poongothai, T.S. Gopenath, S. Manonayaki, Genetics of human male infertility,
Singapore Med. J. 50 (2009) 336–347.
[4] M.M. Matzuk, D.J. Lamb, The biology of infertility: research advances and clinical
challenges, Nat. Med. 14 (2008) 1197–1213.
[5] J. Yu, Z. Chen, Y. Ni, Z. Li, CFTR mutations in men with congenital bilateral absence
of the vas deferens (CBAVD): a systemic review and meta-analysis, Hum. Reprod.
27 (2012) 25–35.
[6] K.L. O'Flynn O'Brien, A.C. Varghese, A. Agarwal, The genetic causes of male factor
infertility: a review, Fertil. Steril. 93 (2010) 1–12.
[7] D. Jamsai, M.K. O'Bryan, Mouse models in male fertility research, Asian J. Androl.
13 (2011) 139–151.
[8] R.H. Martin, Cytogenetic determinants of male fertility, Hum. Reprod. Update 14
(2008) 379–390.
[9] T. Huynh, R. Mollard, A. Trounson, Selected genetic factors associated with male
infertility, Hum. Reprod. Update 8 (2002) 183–198.
[10] A. Massart, W. Lissens, H. Tournaye, K. Stouffs, Genetic causes of spermatogenic
failure, Asian J. Androl. 14 (2012) 40–48.
[11] V.W. Aoki, G.L. Christensen, J.F. Atkins, D.T. Carrell, Identiﬁcation of novel polymor-
phisms in the nuclear protein genes and their relationship with human sperm prot-
amine deﬁciency and severe male infertility, Fertil. Steril. 86 (2006) 1416–1422.
[12] J. Gianotten, A.W. Schimmel, F. van der Veen, M.P. Lombardi, J.C. Meijers, Absence of
mutations in the PCI gene in subfertile men, Mol. Hum. Reprod. 10 (2004) 807–813.
[13] T. Miyamoto, S. Hasuike, L. Yogev, M.R.Maduro, M. Ishikawa, H.Westphal, D.J. Lamb,
Azoospermia in patients heterozygous for a mutation in SYCP3, Lancet 362 (2003)
1714–1719.
[14] O. Pirrello, N. Machev, F. Schimdt, P. Terriou, Y. Menezo, S. Viville, Search for muta-
tions involved in human globozoospermia, Hum. Reprod. 20 (2005) 1314–1318.
[15] K. Stouffs, W. Lissens, H. Tournaye, A. Van Steirteghem, I. Liebaers, SYCP3 muta-
tions are uncommon in patients with azoospermia, Fertil. Steril. 84 (2005)
1019–1020.
[16] G.H. Westerveld, S. Repping, N.J. Leschot, F. van der Veen, M.P. Lombardi, Mutations
in the human BOULE gene are not amajor cause of impaired spermatogenesis, Fertil.
Steril. 83 (2005) 513–515.
[17] G.H. Westerveld, S. Repping, M.P. Lombardi, F. van der Veen, Mutations in the
chromosome pairing gene FKBP6 are not a common cause of non-obstructive
azoospermia, Mol. Hum. Reprod. 11 (2005) 673–675.
[18] F.F. Bier, M. von Nickisch-Rosenegk, E. Ehrentreich-Forster, E. Reiss, J. Henkel, R.
Strehlow, D. Andresen, DNA microarrays, Adv. Biochem. Eng. Biotechnol. 109
(2008) 433–453.
[19] S.F. Grant, H. Hakonarson, Microarray technology and applications in the arena of
genome-wide association, Clin. Chem. 54 (2008) 1116–1124.
[20] E.W. Sayers, T. Barrett, D.A. Benson, E. Bolton, S.H. Bryant, K. Canese, V. Chetvernin,
D.M. Church, M. Dicuccio, S. Federhen, M. Feolo, I.M. Fingerman, L.Y. Geer, W.
Helmberg, Y. Kapustin, S. Krasnov, D. Landsman, D.J. Lipman, Z. Lu, T.L. Madden, T.
Madej, D.R. Maglott, A. Marchler-Bauer, V. Miller, I. Karsch-Mizrachi, J. Ostell, A.
Panchenko, L. Phan, K.D. Pruitt, G.D. Schuler, E. Sequeira, S.T. Sherry, M. Shumway,
K. Sirotkin, D. Slotta, A. Souvorov, G. Starchenko, T.A. Tatusova, L. Wagner, Y.
Wang, W.J. Wilbur, E. Yaschenko, J. Ye, Database resources of the National Center
for Biotechnology Information, Nucleic Acids Res. 40 (2011) D13–D25.
[21] L. Clarke, X. Zheng-Bradley, R. Smith, E. Kulesha, C. Xiao, I. Toneva, B. Vaughan, D.
Preuss, R. Leinonen, M. Shumway, S. Sherry, P. Flicek, The 1000 Genomes Project:
data management and community access, Nat Methods 9 459–462.
[22] I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S.
Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense
mutations, Nat. Methods 7 (2010) 248–249.
[23] P. Kumar, S. Henikoff, P.C. Ng, Predicting the effects of coding non-synonymous
variants on protein function using the SIFT algorithm, Nat. Protoc. 4 (2009)
1073–1082.
[24] M.L. Metzker, Sequencing technologies—the next generation, Nat. Rev. Genet. 11
(2010) 31–46.
[25] C. Gilissen, H.H. Arts, A. Hoischen, L. Spruijt, D.A. Mans, P. Arts, B. van Lier, M.
Steehouwer, J. van Reeuwijk, S.G. Kant, R. Roepman, N.V. Knoers, J.A. Veltman,
H.G. Brunner, Exome sequencing identiﬁes WDR35 variants involved in
Sensenbrenner syndrome, Am. J. Hum. Genet. 87 (2010) 418–423.
[26] P.M. Krawitz, M.R. Schweiger, C. Rodelsperger, C. Marcelis, U. Kolsch, C. Meisel, F.
Stephani, T. Kinoshita, Y. Murakami, S. Bauer, M. Isau, A. Fischer, A. Dahl, M.
Kerick, J. Hecht, S. Kohler, M. Jager, J. Grunhagen, B.J. de Condor, S. Doelken,
H.G. Brunner, P. Meinecke, E. Passarge, M.D. Thompson, D.E. Cole, D. Horn, T.
Roscioli, S. Mundlos, P.N. Robinson, Identity-by-descent ﬁltering of exome
sequence data identiﬁes PIGV mutations in hyperphosphatasia mental retarda-
tion syndrome, Nat. Genet. 42 (2010) 827–829.
[27] K. Musunuru, J.P. Pirruccello, R. Do, G.M. Peloso, C. Guiducci, C. Sougnez, K.V.
Garimella, S. Fisher, J. Abreu, A.J. Barry, T. Fennell, E. Banks, L. Ambrogio, K.
Cibulskis, A. Kernytsky, E. Gonzalez, N. Rudzicz, J.C. Engert, M.A. DePristo, M.J.
Daly, J.C. Cohen, H.H. Hobbs, D. Altshuler, G. Schonfeld, S.B. Gabriel, P. Yue, S.
Kathiresan, Exome sequencing, ANGPTL3 mutations, and familial combined
hypolipidemia, N. Engl. J. Med. 363 (2010) 2220–2227.
[28] S.B. Ng, K.J. Buckingham, C. Lee, A.W. Bigham, H.K. Tabor, K.M. Dent, C.D. Huff, P.T.
Shannon, E.W. Jabs, D.A. Nickerson, J. Shendure, M.J. Bamshad, Exome sequencing
identiﬁes the cause of a mendelian disorder, Nat. Genet. 42 (2010) 30–35.
[29] A.B. Singleton, Exome sequencing: a transformative technology, Lancet Neurol. 10
(2011) 942–946.
[30] T.I.H. Consortium, The International HapMap Project, Nature 426 (2003) 789–796.[31] A. Bloch-Zupan, X. Jamet, C. Etard, V. Laugel, J. Muller, V. Geoffroy, J.P. Strauss, V.
Pelletier, V.Marion, O. Poch, U. Strahle, C. Stoetzel, H. Dollfus, Homozygositymapping
and candidate prioritization identifymutations,missed bywhole-exome sequencing,
in SMOC2, causingmajor dental developmental defects, Am. J. Hum. Genet. 89 (2011)
773–781.
[32] R. Nielsen, J.S. Paul, A. Albrechtsen, Y.S. Song, Genotype and SNP calling from
next-generation sequencing data, Nat. Rev. Genet. 12 (2011) 443–451.
[33] A.H. Dam, I. Feenstra, J.R. Westphal, L. Ramos, R.J. van Golde, J.A. Kremer,
Globozoospermia revisited, Hum. Reprod. Update 13 (2007) 63–75.
[34] M. Ikawa, N. Inoue, A.M. Benham, M. Okabe, Fertilization: a sperm's journey to
and interaction with the oocyte, J. Clin. Invest. 120 (2010) 984–994.
[35] D.T. Carrell, B.R. Emery, L. Liu, Characterization of aneuploidy rates, protamine levels,
ultrastructure, and functional ability of round-headed sperm from two siblings and
implications for intracytoplasmic sperm injection, Fertil. Steril. 71 (1999) 511–516.
[36] N. Machev, P. Gosset, S. Viville, Chromosome abnormalities in sperm from infer-
tile men with normal somatic karyotypes: teratozoospermia, Cytogenet. Genome
Res. 111 (2005) 352–357.
[37] S. Viville, R. Mollard, M.L. Bach, C. Falquet, P. Gerlinger, S. Warter, Do morpholog-
ical anomalies reﬂect chromosomal aneuploidies?: case report, Hum. Reprod. 15
(2000) 2563–2566.
[38] M.R. Banker, P.M. Patel, B.V. Joshi, P.B. Shah, R. Goyal, Successful pregnancies and
a live birth after intracytoplasmic sperm injection in globozoospermia, J. Hum.
Reprod. Sci. 2 (2009) 81–82.
[39] S. Bechoua, A. Chiron, S. Delcleve-Paulhac, P. Sagot, C. Jimenez, Fertilisation and
pregnancy outcome after ICSI in globozoospermic patients without assisted oo-
cyte activation, Andrologia 41 (2009) 55–58.
[40] K. Coetzee, M.L. Windt, R. Menkveld, T.F. Kruger, M. Kitshoff, An intracytoplasmic
sperm injection pregnancy with a globozoospermic male, J. Assist. Reprod. Genet.
18 (2001) 311–313.
[41] E.K. Dirican, A. Isik, K. Vicdan, E. Sozen, Z. Suludere, Clinical pregnancies and
livebirths achieved by intracytoplasmic injection of round headed acrosomeless
spermatozoa with and without oocyte activation in familial globozoospermia:
case report, Asian J. Androl. 10 (2008) 332–336.
[42] Z. Kilani, R. Ismail, S. Ghunaim, H. Mohamed, D. Hughes, I. Brewis, C.L. Barratt,
Evaluation and treatment of familial globozoospermia in ﬁve brothers, Fertil.
Steril. 82 (2004) 1436–1439.
[43] N. Sermondade, E. Hafhouf, C. Dupont, S. Bechoua, C. Palacios, F. Eustache, C.
Poncelet, B. Benzacken, R. Levy, C. Sifer, Successful childbirth after intracytoplasmic
morphologically selected sperm injection without assisted oocyte activation in a
patient with globozoospermia, Hum. Reprod. 26 (2011) 2944–2949.
[44] A.H. Dam, I. Koscinski, J.A. Kremer, C. Moutou, A.S. Jaeger, A.R. Oudakker, H.
Tournaye, N. Charlet, C. Lagier-Tourenne, H. van Bokhoven, S. Viville, Homozygous
mutation in SPATA16 is associated with male infertility in human globozoospermia,
Am. J. Hum. Genet. 81 (2007) 813–820.
[45] G.L. Blatch, M. Lassle, The tetratricopeptide repeat: a structural motif mediating
protein–protein interactions, Bioessays 21 (1999) 932–939.
[46] G. Liu, Q.W. Shi, G.X. Lu, A newly discovered mutation in PICK1 in a human with
globozoospermia, Asian J. Androl. 12 (2010) 556–560.
[47] S.M. Gardner, K. Takamiya, J. Xia, J.G. Suh, R. Johnson, S. Yu, R.L. Huganir,
Calcium-permeable AMPA receptor plasticity is mediated by subunit-speciﬁc
interactions with PICK1 and NSF, Neuron 45 (2005) 903–915.
[48] J.P. Steinberg, K. Takamiya, Y. Shen, J. Xia, M.E. Rubio, S. Yu, W. Jin, G.M. Thomas,
D.J. Linden, R.L. Huganir, Targeted in vivo mutations of the AMPA receptor
subunit GluR2 and its interacting protein PICK1 eliminate cerebellar long-term
depression, Neuron 49 (2006) 845–860.
[49] N. Xiao, C. Kam, C. Shen, W. Jin, J. Wang, K.M. Lee, L. Jiang, J. Xia, PICK1 deﬁciency
causes male infertility in mice by disrupting acrosome formation, J. Clin. Invest.
119 (2009) 802–812.
[50] I. Koscinski, E. Elinati, C. Fossard, C. Redin, J. Muller, J. Velez de la Calle, F. Schmitt,
M. Ben Khelifa, P.F. Ray, Z. Kilani, C.L. Barratt, S. Viville, DPY19L2 deletion as a
major cause of globozoospermia, Am. J. Hum. Genet. 88 (2011) 344–350.
[51] R. Harbuz, R. Zouari, V. Pierre, M. Ben Khelifa, M. Kharouf, C. Coutton, G.
Merdassi, F. Abada, J. Escofﬁer, Y. Nikas, F. Vialard, I. Koscinski, C. Triki, N.
Sermondade, T. Schweitzer, A. Zhioua, F. Zhioua, H. Latrous, L. Halouani, M.
Ouaﬁ, M. Makni, P.S. Jouk, B. Sele, S. Hennebicq, V. Satre, S. Viville, C. Arnoult,
J. Lunardi, P.F. Ray, A recurrent deletion of DPY19L2 causes infertility in man
by blocking sperm head elongation and acrosome formation, Am. J. Hum.
Genet. 88 (2011) 351–361.
[52] A.R. Carson, J. Cheung, S.W. Scherer, Duplication and relocation of the functional
DPY19L2 gene within low copy repeats, BMC Genomics 7 (2006) 45.
[53] W. Gu, F. Zhang, J.R. Lupski, Mechanisms for human genomic rearrangements,
Pathogenetics 1 (2008) 4.
[54] E. Elinati, P. Kuentz, C. Redin, S. Jaber, F. Vanden Meerschaut, J. Makarian, I.
Koscinski, M.H. Nasr-Esfahani, A. Demirol, T. Gurgan, N. Louanjli, N. Iqbal, M.
Bisharah, F.C. Pigeon, H. Gourabi, D. De Briel, F. Brugnon, S.A. Gitlin, J.M. Grillo,
K. Ghaedi, M.R. Deemeh, S. Tanhaei, P. Modarres, B. Heindryckx, M. Benkhalifa,
D. Nikiforaki, S.C. Oehninger, P. De Sutter, J. Muller, S. Viville, Globozoospermia
is mainly due to DPY19L2 deletion via non-allelic homologous recombination in-
volving two recombination hotspots, Hum. Mol. Genet. 21 (2012) 3695–3702.
[55] K. Dieterich, R. Soto Rifo, A.K. Faure, S. Hennebicq, B. Ben Amar, M. Zahi, J. Perrin,
D. Martinez, B. Sele, P.S. Jouk, T. Ohlmann, S. Rousseaux, J. Lunardi, P.F. Ray,
Homozygous mutation of AURKC yields large-headed polyploid spermatozoa
and causes male infertility, Nat. Genet. 39 (2007) 661–665.
[56] S. Kimmins, C. Crosio, N. Kotaja, J. Hirayama, L. Monaco, C. Hoog, M. van Duin, J.A.
Gossen, P. Sassone-Corsi, Differential functions of the Aurora-B and Aurora-C
kinases in mammalian spermatogenesis, Mol. Endocrinol. 21 (2007) 726–739.
1879E. El Inati et al. / Biochimica et Biophysica Acta 1822 (2012) 1873–1879[57] C.J. Tang, C.Y. Lin, T.K. Tang, Dynamic localization and functional implications of
Aurora-C kinase during male mouse meiosis, Dev. Biol. 290 (2006) 398–410.
[58] K. Dieterich, R. Zouari, R. Harbuz, F. Vialard, D. Martinez, H. Bellayou, N. Prisant, A.
Zoghmar, M.R. Guichaoua, I. Koscinski, M. Kharouf, M. Noruzinia, S. Nadiﬁ, A.
Seﬁani, J. Lornage, M. Zahi, S. Viville, B. Sele, P.S. Jouk, M.C. Jacob, D. Escalier, Y.
Nikas, S. Hennebicq, J. Lunardi, P.F. Ray, The Aurora Kinase C c.144delC mutation
causes meiosis I arrest in men and is frequent in the North African population,
Hum. Mol. Genet. 18 (2009) 1301–1309.
[59] M. Ben Khelifa, R. Zouari, R. Harbuz, L. Halouani, C. Arnoult, J. Lunardi, P.F. Ray, A
new AURKC mutation causing macrozoospermia: implications for human sper-
matogenesis and clinical diagnosis, Mol. Hum. Reprod. 17 (2011) 762–768.
[60] M.R. Avenarius, M.S. Hildebrand, Y. Zhang, N.C. Meyer, L.L. Smith, K. Kahrizi, H.
Najmabadi, R.J. Smith, Human male infertility caused by mutations in the
CATSPER1 channel protein, Am. J. Hum. Genet. 84 (2009) 505–510.
[61] J. Jin, N. Jin, H. Zheng, S. Ro, D. Tafolla, K.M. Sanders, W. Yan, Catsper3 and
Catsper4 are essential for sperm hyperactivated motility and male fertility in
the mouse, Biol. Reprod. 77 (2007) 37–44.
[62] H. Qi, M.M. Moran, B. Navarro, J.A. Chong, G. Krapivinsky, L. Krapivinsky, Y. Kirichok,
I.S. Ramsey, T.A. Quill, D.E. Clapham, All four CatSper ion channel proteins are required
for male fertility and sperm cell hyperactivated motility, Proc. Natl. Acad. Sci. U. S. A.
104 (2007) 1219–1223.
[63] D. Ren, B. Navarro, G. Perez, A.C. Jackson, S. Hsu, Q. Shi, J.L. Tilly, D.E. Clapham, A sperm
ion channel required for spermmotility andmale fertility, Nature 413 (2001) 603–609.
[64] A.E. Carlson, R.E. Westenbroek, T. Quill, D. Ren, D.E. Clapham, B. Hille, D.L. Garbers,
D.F. Babcock, CatSper1 required for evoked Ca2+ entry and control of ﬂagellar
function in sperm, Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14864–14868.
[65] Y. Choi, S. Jeon, M. Choi, M.H. Lee, M. Park, D.R. Lee, K.Y. Jun, Y. Kwon, O.H. Lee, S.H.
Song, J.Y. Kim, K.A. Lee, T.K. Yoon, A. Rajkovic, S.H. Shim, Mutations in SOHLH1
gene associate with nonobstructive azoospermia, Hum. Mutat. 31 (2010) 788–793.
[66] D. Ballow, M.L. Meistrich, M. Matzuk, A. Rajkovic, Sohlh1 is essential for sper-
matogonial differentiation, Dev. Biol. 294 (2006) 161–167.
[67] C.M. Saunders, M.G. Larman, J. Parrington, L.J. Cox, J. Royse, L.M. Blayney, K.
Swann, F.A. Lai, PLC zeta: a sperm-speciﬁc trigger of Ca(2+) oscillations in eggs
and embryo development, Development 129 (2002) 3533–3544.
[68] E. Heytens, J. Parrington, K. Coward, C. Young, S. Lambrecht, S.Y. Yoon, R.A.
Fissore, R. Hamer, C.M. Deane, M. Ruas, P. Grasa, R. Soleimani, C.A. Cuvelier, J.Gerris, M. Dhont, D. Deforce, L. Leybaert, P. De Sutter, Reduced amounts and ab-
normal forms of phospholipase C zeta (PLCzeta) in spermatozoa from infertile
men, Hum. Reprod. 24 (2009) 2417–2428.
[69] J. Kashir, M. Konstantinidis, C. Jones, B. Lemmon, H. Chang Lee, R. Hamer, B.
Heindryckx, C.M. Deane, P. De Sutter, R.A. Fissore, J. Parrington, D. Wells, K.
Coward, A maternally inherited autosomal point mutation in human phospholi-
pase C zeta (PLCzeta) leads to male infertility, Hum. Reprod. 27 (2012) 222–231.
[70] L. Lin, P. Philibert, B. Ferraz-de-Souza, D. Kelberman, T. Homfray, A. Albanese, V.
Molini, N.J. Sebire, S. Einaudi, G.S. Conway, I.A. Hughes, J.L. Jameson, C. Sultan, M.T.
Dattani, J.C. Achermann, Heterozygous missense mutations in steroidogenic factor
1 (SF1/Ad4BP, NR5A1) are associated with 46, XY disorders of sex development
with normal adrenal function, J. Clin. Endocrinol. Metab. 92 (2007) 991–999.
[71] D. Lourenco, R. Brauner, L. Lin, A. De Perdigo, G. Weryha, M. Muresan, R.
Boudjenah, G. Guerra-Junior, A.T. Maciel-Guerra, J.C. Achermann, K. McElreavey,
A. Bashamboo, Mutations in NR5A1 associated with ovarian insufﬁciency, N.
Engl. J. Med. 360 (2009) 1200–1210.
[72] A. Bashamboo, B. Ferraz-de-Souza, D. Lourenco, L. Lin, N.J. Sebire, D. Montjean, J.
Bignon-Topalovic, J. Mandelbaum, J.P. Siffroi, S. Christin-Maitre, U. Radhakrishna,
H. Rouba, C. Ravel, J. Seeler, J.C. Achermann, K. McElreavey, Human male infertility
associated with mutations in NR5A1 encoding steroidogenic factor 1, Am. J. Hum.
Genet. 87 (2010) 505–512.
[73] R.M. Sharpe, N.E. Skakkebaek, Are oestrogens involved in falling sperm counts
and disorders of the male reproductive tract? Lancet 341 (1993) 1392–1395.
[74] N.E. Skakkebaek, E. Rajpert-DeMeyts, K.M.Main, Testicular dysgenesis syndrome: an
increasingly common developmental disorder with environmental aspects, Hum.
Reprod. 16 (2001) 972–978.
[75] K.I. Aston, D.T. Carrell, Genome-wide study of single-nucleotide polymorphisms
associated with azoospermia and severe oligozoospermia, J. Androl. 30 (2009)
711–725.
[76] K.I. Aston, C. Krausz, I. Laface, E. Ruiz-Castane, D.T. Carrell, Evaluation of 172 candidate
polymorphisms for associationwith oligozoospermia or azoospermia in a large cohort
of men of European descent, Hum. Reprod. 25 (2010) 1383–1397.
[77] Z. Hu, Y. Xia, X. Guo, J. Dai, H. Li, H. Hu, Y. Jiang, F. Lu, Y. Wu, X. Yang, B. Yao, C. Lu,
C. Xiong, Z. Li, Y. Gui, J. Liu, Z. Zhou, H. Shen, X. Wang, J. Sha, A genome-wide as-
sociation study in Chinese men identiﬁes three risk loci for non-obstructive azo-
ospermia, Nat. Genet. 44 (2011) 183–186.
